ADMA Biologics (NASDAQ: ADMA), typically one of the more under-the-radar coronavirus stocks, was very much on the radar of many investors on Thursday. The company's shares popped by over 5% on an otherwise generally flat day for stocks in general, thanks to an estimates-beating second quarter.

ADMA attracted a degree of renown in 2020 after its convalescent plasma won Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) to fight COVID. The company reported those quarterly figures after market hours on Thursday. They reveal that the company earned just under $34 million in revenue for the period, up a very healthy 90% on a year-over-year basis.

As for the bottom line, ADMA booked a net loss of nearly $14 million ($0.07 per share). Yet this was an improvement over 2021's Q2 when the company posted a shortfall of almost $19 million.

Continue reading

Source Fool.com